Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Adult Ph+ LAL With BMS-354825

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with Ph+ and/or BCR/ABL+ ALL~* Age ≥18 years old~* De novo ALL (within 14 days from diagnosis)~* No prior treatment with any anti-leukemic drugs with the exception of steroids for no more than 14 days (including the 7-day pretreatment already scheduled in the protocol)~* WHO performance status ≤2~* Absence of central nervous system (CNS) leukemia~* Normal serum level of potassium, total calcium corrected for serum albumin magnesium and phosphorus, or correctable with supplements~* ALT and AST ≤2.5 x ULN or ≤5.0 x ULN if considered due to leukemia~* Alkaline phosphatase ≤2.5 x ULN unless considered to leukemia~* Serum bilirubin ≤2 x ULN~* Serum creatinine ≤3 x ULN~* Serum amylase ≤1.5 x ULN and serum lipase ≤1.5 x ULN~* Normal cardiac function~* Written informed consent prior to any study procedures being performed.~Exclusion Criteria:~* Impaired cardiac function, including any one of the following:~* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BMS-354825 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection)~* Use of therapeutic warfarin~* Acute or chronic liver or renal disease considered unrelated to leukemia~* Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol~* Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM¬CSF) ≤1 week prior to starting study drug~* Patients who are currently receiving treatment with any of the medications listed in Appendix F and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in Appendix F have the potential to prolong the QT interval.~* Patients who have received any anti-leukemic agents and treatments including steroids for more than 14 days including 7 days pretreatment that is part of the protocol~* Patients who have received any investigational drug in the last 2 weeks~* Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who have not recovered from side effects of such therapy~* Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of BMS-354825). Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug~* Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)~* Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention~* Non compliant to oral medication patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete